We maintain our ‘Accumulate’ rating on Lupin Ltd. with a revised target price of Rs 2,162, valuing at 28x FY27E P/E. Timely launches of injectables and inhalation products will be further triggers to our earnings estimates.
Key risks:
US price erosion, higher competition in key products and escalation of compliance issues at Taradeep/ Mandideep Unit-I plants.
PokerBaazi, in a post on X, said user funds remain completely safe and will be accessible for withdrawals. WinZO, which…
Key Takeaways The Central Reserve Bank of El Salvador has increased its total gold holdings to 58,105 troy ounces from…
Elon Musk’s long-standing battle with OpenAI has a new participant: Apple. On Tuesday, Apple found itself the latest target of…